Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Noxon
Noxon Overview
Noxon develops a novel drug for oral treatment of fibrotic lung diseases. The developed drug, 3-cabamoyl-proxyl, is a stable organic radical belonging to the nitroxides group.
Its product, 3-CP, which has a unique antioxidant property, has been shown to reduce airway inflammation, airway hyper-responsiveness, and other inflammatory mediators of the lung tissues, as seen in animal models of allergic asthma.